Servier completes Day One acquisition, adding OJEMDA to its US oncology portfolio
Servier has closed its Day One acquisition, taking control of U.S.-marketed OJEMDA and adding a rare cancer pipeline while ex-U.S. rights remain licensed to Ipsen.
Read insight